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Abstract
To identify the molecules applicable as novel tumor biomarkers, we performed gene expression profile analysis of various
human cancers whose tumor cells were purified by laser microdissection. Through a subsequent systematic approach using
tissue microarray, RNA interference, and high throughput enzyme-linked immunosorbent assay techniques as well as
bioinformatics, we have identified a set of molecules that fall into the category of oncoantigens. These molecules are
potentially promising candidates for the development of new diagnostic biomarkers. We introduce our sophisticated and
integrated cancer genomics strategy for developing new cancer biomarkers.










































































PKP3, ANLN, SEZ6L2, NMU, CDCA1, KNTC2, FGFR1OP, IMP-1,
KIF4A, DKK1, CDCA8, AURKB, HJURP, hTERT, LY6K, DLX5,
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